| Dr Charles E Hendrix, Jr, MD | |
|
700 Willow St Ste 202, Vincennes, IN 47591-1029 | |
| (812) 885-0520 | |
| (812) 885-0517 |
| Full Name | Dr Charles E Hendrix, Jr |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 44 Years |
| Location | 700 Willow St Ste 202, Vincennes, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437101128 | NPI | - | NPPES |
| 100154890 | Medicaid | IN | |
| 118323 | Other | IN | HEALTHLINK |
| P00851310 | Other | IN | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 01030371A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Home Care Services Of Vincennes In | Vincennes, IN | Home health agency |
| Guardian Angel Home Health Care Inc | Bicknell, IN | Home health agency |
| Lawrence County Health Dept | Lawrenceville, IL | Home health agency |
| Aseracare Hospice | Evansville, IN | Hospice |
| Heart To Heart Hospice Of Southwest Indiana Llc | Jasper, IN | Hospice |
| Good Samaritan Hospice | Vincennes, IN | Hospice |
| Good Samaritan Hospital | Vincennes, IN | Hospital |
| Crawford Memorial Hospital | Robinson, IL | Hospital |
| Lawrence County Memorial Hospital | Lawrenceville, IL | Hospital |
| Daviess Community Hospital | Washington, IN | Hospital |
| Bridgepointe Health Campus | Vincennes, IN | Nursing home |
| Willow Manor | Vincennes, IN | Nursing home |
| Gentlecare Of Vincennes | Vincennes, IN | Nursing home |
| Lodge Of The Wabash | Vincennes, IN | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Good Samaritan Hospital Physician Services Inc | 3971671330 | 129 |
| Legacy Healthcare Services Inc | 2163339722 | 2654 |
News Archive
Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.
Today's headlines reflect more analysis and debate regarding continuing health reform implementation efforts.
Pharmaceuticals, Inc. today announced interim results of a randomized, open‐label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer. Based on this interim analysis, the study demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival (PFS) in patients receiving single-agent ridaforolimus compared to patients receiving standard-of-care treatment.
A bioceramic implant has proved to stimulate regeneration of natural skull bone, so that even large cranial defects can be repaired in a way that has not been possible before. The research, led from the University of Gothenburg, is now presented in the scientific journal PNAS.
› Verified 4 days ago
| Entity Name | Good Samaritan Hospital Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649432071 PECOS PAC ID: 3971671330 Enrollment ID: O20081013000182 |
News Archive
Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.
Today's headlines reflect more analysis and debate regarding continuing health reform implementation efforts.
Pharmaceuticals, Inc. today announced interim results of a randomized, open‐label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer. Based on this interim analysis, the study demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival (PFS) in patients receiving single-agent ridaforolimus compared to patients receiving standard-of-care treatment.
A bioceramic implant has proved to stimulate regeneration of natural skull bone, so that even large cranial defects can be repaired in a way that has not been possible before. The research, led from the University of Gothenburg, is now presented in the scientific journal PNAS.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charles E Hendrix, Jr, MD 1160 E Saint Clair St, Vincennes, IN 47591-4853 Ph: (812) 885-3325 | Dr Charles E Hendrix, Jr, MD 700 Willow St Ste 202, Vincennes, IN 47591-1029 Ph: (812) 885-0520 |
News Archive
Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.
Today's headlines reflect more analysis and debate regarding continuing health reform implementation efforts.
Pharmaceuticals, Inc. today announced interim results of a randomized, open‐label, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer. Based on this interim analysis, the study demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival (PFS) in patients receiving single-agent ridaforolimus compared to patients receiving standard-of-care treatment.
A bioceramic implant has proved to stimulate regeneration of natural skull bone, so that even large cranial defects can be repaired in a way that has not been possible before. The research, led from the University of Gothenburg, is now presented in the scientific journal PNAS.
› Verified 4 days ago
Dr. Alan D Stewart, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 520 S 7th St, Vincennes, IN 47591 Phone: 812-885-3601 Fax: 812-885-3614 | |
Mr. Elias Victor I Impens, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 520 S 7th St, Vincennes, IN 47591 Phone: 812-882-5220 Fax: 812-885-3917 | |
Mark E. Pajeau, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 520 S 7th St, Vincennes, IN 47591 Phone: 812-886-6565 Fax: 812-886-6566 | |
Richard Walter, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 1813 Willow St, Suite 5 B, Vincennes, IN 47591 Phone: 812-882-2703 Fax: 812-882-2760 | |
Andrei Mihai Croitoru, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 520 S 7th St, Good Samaritan Hospital, Vincennes, IN 47591 Phone: 812-885-2500 | |
Renee L Bartlett, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 520 S 7th St, Vincennes, IN 47591 Phone: 812-886-6565 Fax: 812-886-6566 | |
Billy Powell Jr., MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 520 S 7th St, Vincennes, IN 47591 Phone: 812-882-5220 |